Melanotan II and Cosmetic Peptides

What Melanotan II Is

Melanotan II (MT2) is a synthetic analog of alpha-MSH - a naturally occurring peptide that stimulates melanin production in the skin. MT2 was originally developed as a potential sunless tanning agent and a treatment for sexual dysfunction. Neither application proceeded to pharmaceutical approval; the compound entered the research peptide market instead.

MT2 acts on two distinct receptor types:

MC1R (melanocortin receptor 1): Found on melanocytes in the skin. Activation triggers melanogenesis - the production of melanin pigment - producing a tan without requiring UV-induced DNA damage as the stimulus. Some UV exposure (“activation” in user parlance) accelerates the process, but is not strictly required for tanning.

MC4R (melanocortin receptor 4): Found in the hypothalamus and other central nervous system regions. MC4R activation produces the secondary effects associated with MT2: appetite suppression, increased libido, and in some users, spontaneous erections.

The dual-receptor action creates a compound profile that bodybuilders find useful for contest preparation: tanning without sun exposure, appetite suppression during a calorie deficit, and a cosmetically beneficial baseline.

Protocol Design

MT2 requires reconstitution. Standard vials are 10 mg lyophilised peptide; typical reconstitution is with 2 mL bacteriostatic water, giving a 5 mg/mL (5,000 mcg/mL) concentration.

Loading phase (building melanin density):

• Starting dose: 100–250 mcg subcutaneous, injected in the evening to allow nausea and flushing to pass during sleep
• Increase by 100–250 mcg every 2–3 days as tolerated
• Target loading dose: 500–1,000 mcg daily
• Duration: Continue until desired tan depth is reached, typically 2–6 weeks depending on baseline skin tone, dose, and sun exposure
• Brief UV exposure (10–20 minutes of natural sun or a short sun-bed session) in the 24–48 hours after injection accelerates pigmentation significantly

Maintenance phase:

• Once target tan depth is reached, reduce to 500–1,000 mcg 1–2 times per week
• Minimal or no UV exposure needed to maintain pigment once melanin density is established

Important: Start at the low end. The nausea, flushing, and facial redness from MC4R activation at high doses are unpleasant enough to cause abandonment if escalated too quickly.

Side Effect Profile

Nausea and flushing: The most common side effects, caused by MC4R activation. Worst in the first 1–2 hours after injection. Evening dosing with a light pre-injection meal reduces severity. Both effects diminish significantly as the dose is maintained over time - the body adapts.

Spontaneous erections: A documented effect of MC4R activation, particularly at higher doses. Typically transient and disappears once the active dose effect wears off.

Yawning and stretching: Reported by many users, particularly shortly after injection.

Darkening of moles, freckles, and scars: MC1R activation increases melanin production uniformly across melanocytes, including in existing moles. This is the most clinically important monitoring point.

Appetite suppression: Useful in a cut; can be problematic if it impairs protein intake.

Mole and Lesion Monitoring: The Non-Negotiable

Melanotan II stimulates melanin production in all melanocytes, including atypical ones. There are documented case reports of melanocytic nevi (moles) changing in size, colour, and morphology during MT2 use. In several cases, melanoma was subsequently diagnosed. The causal relationship between MT2 and de novo melanoma is not established - it is not clear whether MT2 induced malignant transformation or accelerated existing pre-malignant lesions - but the biological plausibility is sufficient to warrant monitoring.

Before starting MT2:

• Photograph or document all existing moles with a dermatologist baseline if possible
• If you have a personal or family history of melanoma or dysplastic nevi, MT2 is contraindicated
• Know what ABCDE criteria for melanoma look like: Asymmetry, Border irregularity, Colour variation, Diameter larger than 6 mm, Evolving appearance

During MT2 use:

• Check moles regularly - every 2 weeks minimum
• Any mole that changes in colour, size, border, or that begins to itch, bleed, or crust requires immediate dermatological assessment. Do not wait for a routine appointment.
• This is not excessive caution. Melanoma is one of the more dangerous skin cancers precisely because it is highly treatable when caught early and difficult to treat when caught late.

Positioning Within Training

MT2 is a cosmetic compound. It does not increase performance, muscle mass, or strength. Its practical value is:

• Tanning for contest preparation or aesthetic goals without extended UV exposure
• Appetite suppression as a minor adjunct in cutting phases
• Convenience for users who cannot or prefer not to achieve tan through sun exposure

It is not a compound that produces anabolic effects or alters training adaptation in any meaningful way. Users should evaluate whether the cosmetic benefit justifies the injection protocol, the nausea management during loading, and the ongoing mole-monitoring commitment. For most non-competitive users, the practical value is limited.

For contest-preparation contexts where appearance is being optimised at every margin, MT2 has a legitimate place in the toolkit. The monitoring requirement is simply a cost of using it responsibly.